Clinical Trial Detail

NCT ID NCT02263508
Title MK-3475 With or Without Talimogene Laherparepvec in Unresected Melanoma
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Amgen
Indications

melanoma

Therapies

Pembrolizumab

Talimogene laherparepvec

Age Groups: adult

No variant requirements are available.